GC
MCRB icon

Globeflex Capital’s Seres Therapeutics MCRB Stock Holding History

Globeflex Capital’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,245
Closed -$661K – 495
2016
Q1 		$661K Buy
+1,245
New +$650K 0.18% 199

Other funds holding MCRB

FVFIGP
Flagship Ventures Fund IV General Partner Cambridge, Massachusetts $585M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Globeflex Capital's MCRB Position: Q2 2016 in Review

Globeflex Capital sold out of Seres Therapeutics (MCRB) in Q2 2016, closing a stake of 1,245 shares — an estimated $661K sold.

Globeflex Capital first reported a position in MCRB in Q1 2016 and held it in 1 quarter. The position peaked at $661K in Q1 2016. 91 funds tracked by Wall St. Rank hold MCRB as of Q2 2016.

  • Globeflex Capital reported no remaining Seres Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Globeflex Capital sold 1,245 Seres Therapeutics shares in Q2 2016, an estimated $661K.
  • Globeflex Capital first reported a position in Seres Therapeutics in Q1 2016 and held it in 1 quarter.
  • Globeflex Capital's Seres Therapeutics position peaked at $661K in Q1 2016.
  • 91 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2016.

Based on Globeflex Capital's 13F filing for Q2 2016, filed 10 Aug 2016.